197 related articles for article (PubMed ID: 30154228)
21. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
Juchum M; Günther M; Laufer SA
Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
[TBL] [Abstract][Full Text] [Related]
22. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
Hashida S; Yamamoto H; Shien K; Ohtsuka T; Suzawa K; Maki Y; Furukawa M; Soh J; Asano H; Tsukuda K; Miyoshi S; Kanazawa S; Toyooka S
Oncol Rep; 2015 Mar; 33(3):1499-504. PubMed ID: 25607753
[TBL] [Abstract][Full Text] [Related]
23. Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report.
Kozlov V; Karpov I; Kovalenko S; Shamanin V
Exp Oncol; 2017 Jul; 39(2):155-156. PubMed ID: 29483495
[TBL] [Abstract][Full Text] [Related]
24. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.
Koizumi H; Yamada T; Takeuchi S; Nakagawa T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Yano S
J Thorac Oncol; 2012 Jul; 7(7):1078-85. PubMed ID: 22592212
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
Sawai A; Chandarlapaty S; Greulich H; Gonen M; Ye Q; Arteaga CL; Sellers W; Rosen N; Solit DB
Cancer Res; 2008 Jan; 68(2):589-96. PubMed ID: 18199556
[TBL] [Abstract][Full Text] [Related]
26. Discovery of mobocertinib, a potent, oral inhibitor of EGFR exon 20 insertion mutations in non-small cell lung cancer.
Huang WS; Li F; Gong Y; Zhang Y; Youngsaye W; Xu Y; Zhu X; Greenfield MT; Kohlmann A; Taslimi PM; Toms A; Zech SG; Zhou T; Das B; Jang HG; Tugnait M; Ye YE; Gonzalvez F; Baker TE; Nadworny S; Ning Y; Wardwell SD; Zhang S; Gould AE; Hu Y; Lane W; Skene RJ; Zou H; Clackson T; Narasimhan NI; Rivera VM; Dalgarno DC; Shakespeare WC
Bioorg Med Chem Lett; 2023 Jan; 80():129084. PubMed ID: 36423823
[TBL] [Abstract][Full Text] [Related]
27. TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations.
Hasako S; Terasaka M; Abe N; Uno T; Ohsawa H; Hashimoto A; Fujita R; Tanaka K; Okayama T; Wadhwa R; Miyadera K; Aoyagi Y; Yonekura K; Matsuo K
Mol Cancer Ther; 2018 Aug; 17(8):1648-1658. PubMed ID: 29748209
[TBL] [Abstract][Full Text] [Related]
28. EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
Yu G; Xie X; Sun D; Geng J; Fu F; Zhang L; Wang H
Int J Clin Exp Pathol; 2015; 8(7):8603-6. PubMed ID: 26339441
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
[TBL] [Abstract][Full Text] [Related]
30. Durable Response of Low-Dose Afatinib plus Cetuximab in an Adenocarcinoma Patient with a Novel EGFR Exon 20 Insertion Mutation.
Fang W; Huang Y; Gan J; Shao YW; Zhang L
J Thorac Oncol; 2019 Oct; 14(10):e220-e221. PubMed ID: 31558231
[No Abstract] [Full Text] [Related]
31. Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC.
van Veggel B; de Langen AJ; Hashemi SMS; Monkhorst K; Heideman DAM; Thunnissen E; Smit EF
J Thorac Oncol; 2018 Aug; 13(8):1222-1226. PubMed ID: 29702285
[TBL] [Abstract][Full Text] [Related]
32. Afatinib in the Treatment of Advanced Non-Small Cell Lung Cancer with Rare EGFR (in exon 18-T179X) Mutation - a Case Report.
Čoupková H; Vyzula R
Klin Onkol; 2018; 31(5):380-383. PubMed ID: 30541326
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy.
Marrugal Á; Ferrer I; Quintanal-Villalonga Á; Ojeda L; Pastor MD; García-Luján R; Carnero A; Paz-Ares L; Molina-Pinelo S
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762133
[TBL] [Abstract][Full Text] [Related]
34. [Plasma relative abundance of epidermal growth factor receptor mutations predicts clinical response to epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced lung adenocarcinoma].
Xu HY; Lai QQ; Su SS; Zhou LP; Ye JR; Zhang DQ; Xie YP; Li YP
Zhonghua Nei Ke Za Zhi; 2019 Jan; 58(1):49-55. PubMed ID: 30605951
[No Abstract] [Full Text] [Related]
35. EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP).
Cardona AF; Rojas L; Zatarain-Barrón ZL; Freitas HC; Granados ST; Castillo O; Oblitas G; Corrales L; Castro CD; Ruiz-Patiño A; Martín C; Pérez MA; González L; Chirinos L; Vargas C; Carranza H; Otero J; Rodriguez J; Rodriguez J; Archila P; Lema M; Acosta Madiedo J; Karachaliu N; Wills B; Pino LE; de Lima V; Rosell R; Arrieta O;
Lung Cancer; 2018 Nov; 125():265-272. PubMed ID: 30429031
[TBL] [Abstract][Full Text] [Related]
36. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
Russo A; Franchina T; Ricciardi G; Battaglia A; Picciotto M; Adamo V
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30901844
[TBL] [Abstract][Full Text] [Related]
37. Associations between clinical data and computed tomography features in patients with epidermal growth factor receptor mutations in lung adenocarcinoma.
Cao Y; Xu H; Liao M; Qu Y; Xu L; Zhu D; Wang B; Tian S
Int J Clin Oncol; 2018 Apr; 23(2):249-257. PubMed ID: 28988295
[TBL] [Abstract][Full Text] [Related]
38. NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors.
Yang M; Xu X; Cai J; Ning J; Wery JP; Li QX
Int J Cancer; 2016 Jul; 139(1):171-6. PubMed ID: 26891175
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation.
Iwamoto Y; Ichihara E; Hara N; Nakasuka T; Ando C; Umeno T; Hirabae A; Maeda Y; Kiura K
Jpn J Clin Oncol; 2019 Aug; 49(8):786-788. PubMed ID: 31187861
[TBL] [Abstract][Full Text] [Related]
40. Treatment exceeds expectations in a patient with non-small cell lung adenocarcinoma with an EGFR exon 20 mutation.
McAuliffe A; Bindal P; Haley M; Vredenburgh J
J Oncol Pharm Pract; 2020 Jan; 26(1):206-208. PubMed ID: 30760168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
